Literature DB >> 17768181

Preventing stroke among children with sickle cell anemia: an analysis of strategies that involve transcranial Doppler testing and chronic transfusion.

Maitreyi Mazumdar1, Matthew M Heeney, Colin M Sox, Tracy A Lieu.   

Abstract

BACKGROUND: Transcranial Doppler ultrasonography can identify children with sickle cell anemia who are at elevated risk of stroke and may benefit from chronic transfusions. Uncertainty about the risk/benefit trade-offs of chronic transfusion has led some clinicians to decide not to offer transcranial Doppler ultrasonography screening.
OBJECTIVES: Our goals were to (1) compare the projected benefits and risks of 6 primary stroke-prevention strategies, (2) estimate the optimal frequency of screening, and (3) identify key assumptions that influence the risk/benefit relationship.
METHODS: We designed a decision model to compare 6 primary stroke-prevention strategies: (1) annual transcranial Doppler ultrasonography screening until age 16 with children at high risk of stroke receiving monthly transfusion for life; (2) annual transcranial Doppler ultrasonography until age 16 with transfusions until age 18; (3) biannual transcranial Doppler ultrasonography until age 16 with transfusions until age 18; (4) annual transcranial Doppler ultrasonography until age 10 with transfusion until age 18; (5) 1-time screening at age 2 with transfusion until age 18; and (6) no intervention. Assumptions were derived from the published literature.
RESULTS: For a hypothetical cohort of 2-year-old children, the optimal strategy was transcranial Doppler ultrasonography screening annually until age 10 with children at high risk receiving monthly transfusions until age 18. The optimal strategy would prevent 32% of strokes predicted to occur without intervention. The optimal strategy led to benefits similar to more intensive screening and transfusion strategies but resulted in fewer adverse events. All the intervention strategies resulted in net losses in life expectancy, because the projected mortality averted by stroke prevention was outweighed by the projected increase in mortality from transfusion. Results were sensitive to adherence rates to iron-chelation therapy.
CONCLUSIONS: The optimal stroke-prevention strategy was projected to be annual transcranial Doppler ultrasonography screening until age 10 with transfusion for children at high risk until age 18. Better adherence to chelation therapy would improve life expectancy in all intervention strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17768181     DOI: 10.1542/peds.2006-2002

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

1.  Variation in cerebral blood flow velocity with cerebral perfusion pressure >40 mm Hg in 42 children with severe traumatic brain injury.

Authors:  Shaji Philip; Onuma Chaiwat; Yuthana Udomphorn; Anne Moore; Jerry J Zimmerman; William Armstead; Monica S Vavilala
Journal:  Crit Care Med       Date:  2009-11       Impact factor: 7.598

2.  Sickle cell disease with double stroke in a Moroccan family.

Authors:  Khalil Hamzi; Afaf Ben Itto; Zineb Jouhadi; Ilham Slassi; Sellama Nadifi
Journal:  J Mol Neurosci       Date:  2013-01-23       Impact factor: 3.444

3.  Decision analysis of treatment strategies in children with severe sickle cell disease.

Authors:  Sarah H O'Brien; Jane S Hankins
Journal:  J Pediatr Hematol Oncol       Date:  2009-11       Impact factor: 1.289

Review 4.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

Review 5.  Cerebrovascular disease and stroke.

Authors:  J Pappachan; F J Kirkham
Journal:  Arch Dis Child       Date:  2008-06-30       Impact factor: 3.791

6.  Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents.

Authors:  Etheresia Pretorius; Janette Bester; Natasha Vermeulen; Boguslaw Lipinski; George S Gericke; Douglas B Kell
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

7.  Sickle cell disease: management options and challenges in developing countries.

Authors:  Daniel Ansong; Alex Osei Akoto; Delaena Ocloo; Kwaku Ohene-Frempong
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-11-04       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.